Assessment of serum levels of malondialdehyde and interleukine-5 in asthmatic patients receiving corticosteroid therapy

Abstract

Asthma is a very common chronic disease involving the respiratory system in which the airways occasionally constrict, become inflamed, and are lined with excessive amounts of mucus, often in response to one or more triggers. The current work represents an experimental study that was conducted in Tikrit Teaching Hospital, during the period from April 2008 to the end of November 2008. Around 90 individuals were included in this study from both genders, their ages were from 18 to 80 years. A total of 70 patients with mild and moderate asthma were included in this study from both genders. Their age range from 18 -80 years. It is evident from this study that the highest percentage was 69.2% in patients with mild asthma on steroids was females and 52.6% in asthmatic patients without steroid therapy males, while in mild asthma without steroids and moderate asthma on steroids the percentage is the same in both genders and which was 37.5% and 50% respectively. There was no significant difference between different study groups regarding gender distribution (P > 0.05). The mean level of serum malondialdehyde was 3.39 ± 0.42 in mild asthma without steroid therapy, 4.03 ± 0.18 in moderate asthma without steroid therapy, 2.18 ± 0.12 in mild asthma on steroid therapy, while 2.77 ± 0.56 in moderate asthma on steroid therapy and 3.33 ± 0.16 in the control group. reveals that the mean level of serum interleukin-5 was10.78 ± 3.19 in mild asthma without steroid therapy, 16.65 ± 4.99 pg/ml in moderate asthma without steroid therapy, 3.94 ± 0.82 pg/ml in mild asthma on steroid therapy, while 4.10 ± 1.08 pg/ml in moderate asthma on steroid therapy and 3.32 ± 0.38 pg/ml in the control group.